glp-1 list of glp 1 for weight loss Are Serious Anesthesia Risks of Semaglutide and Other GLP The number of GLP-1 prescriptions

[20,21] However, since GLP-1 were not initially developed with pregnancy, safety and efficacy data in pregnant remain limited

With no other semaglutide patents listed in Canadas Patent Register, generic and biosimilar players now have a clear path, like Sandozs CEO has already signaling plans to launch a GLP-1 generic in Canada as soon as exclusivity ends in January 2026

The statements presented in this article have not been evaluated by the Food and Drug Administration

This limits the affordability of many patients, especially from low- and middle-income groups and those who do not have medical insurance, restricting market growth